Zevra officer sells 1,794 shares in open market
Zevra Therapeutics Chief Legal & Compliance officer Rahsaan Thompson reported an open-market sale of 1,794 shares of common stock at $11.30 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Zevra Therapeutics Chief Legal & Compliance officer Rahsaan Thompson reported an open-market sale of 1,794 shares of common stock at $11.30 per share. After this transaction, he directly holds 48,125 shares. The sale was executed pursuant to a Rule 10b5-1(c) trading plan adopted on 01-08-2026, indicating it was pre-scheduled rather than a discretionary trade.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 1,794 | $11.30 | $20K |
Footnotes (1)
- F1. Adoption date of referenced 10b5-1(c) plan is: 01-08-2026
Key Figures
Key Terms
Rule 10b5-1(c) plan regulatory
open-market sale financial
Common Stock financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Zevra Therapeutics (ZVRA) report for Rahsaan Thompson?
Was the Zevra Therapeutics insider sale made under a Rule 10b5-1 trading plan?
What role does Rahsaan Thompson hold at Zevra Therapeutics (ZVRA)?
AI-generated analysis. How Rhea-AI works. Not financial advice.